Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 · kind B2 · utility
2Cited by
16References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 22, 2020 |
| Grant date | May 16, 2023 |
| Priority date | — |
| Expiry date | May 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.